{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:30:17Z","timestamp":1790101817468,"version":"4.0.1"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Dr. Reza Mohammadhassan","award":["1403MeSc001"],"award-info":[{"award-number":["1403MeSc001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-01884-x","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T07:42:05Z","timestamp":1738914125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Genetic advancements in breast cancer treatment: a review"],"prefix":"10.1007","volume":"16","author":[{"given":"Marzieh","family":"Shokoohi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf","family":"Sedaghatshoar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homaira","family":"Arian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Mokarami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Habibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Bamarinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"6","key":"1884_CR1","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3390\/v13061128","volume":"13","author":"A Kwan","year":"2021","unstructured":"Kwan A, Winder N, Muthana M. Oncolytic virotherapy treatment of breast cancer: barriers and recent advances. Viruses. 2021;13(6):1128.","journal-title":"Viruses"},{"issue":"3","key":"1884_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.clbc.2020.02.001","volume":"20","author":"SM Albeshan","year":"2020","unstructured":"Albeshan SM, et al. Can breast self-examination and clinical breast examination along with increasing breast awareness facilitate earlier detection of breast cancer in populations with advanced stages at diagnosis? Clin Breast Cancer. 2020;20(3):194\u2013200.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"1884_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1884_CR4","unstructured":"C.C.f.D.C.a prevention. Breast cancer statistics. 2024. https:\/\/www.cdc.gov\/breast-cancer\/statistics\/index.html#:~:text=Breast%20cancer%20is%20the%20second%20leading%20cause%20of%20cancer%20death,leading%20cause%20of%20cancer%20deathb. Accessed 15 Dec 2024."},{"issue":"6","key":"1884_CR5","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3322\/caac.21583","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438\u201351.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"1884_CR6","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1093\/humrep\/del201","volume":"21","author":"R Anderson","year":"2006","unstructured":"Anderson R, et al. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod. 2006;21(10):2583\u201392.","journal-title":"Hum Reprod"},{"issue":"9","key":"1884_CR7","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/annonc\/mdq683","volume":"22","author":"H Azim Jr","year":"2011","unstructured":"Azim H Jr, et al. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol. 2011;22(9):1939\u201347.","journal-title":"Ann Oncol"},{"issue":"4","key":"1884_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2174\/1566523218666180910163805","volume":"18","author":"SM O'Bryan","year":"2018","unstructured":"O\u2019Bryan SM, Mathis JM. Oncolytic virotherapy for breast cancer treatment. Curr Gene Ther. 2018;18(4):192\u2013205.","journal-title":"Curr Gene Ther"},{"issue":"22","key":"1884_CR9","doi-asserted-by":"publisher","first-page":"36331","DOI":"10.18632\/oncotarget.16752","volume":"8","author":"M-Y Park","year":"2017","unstructured":"Park M-Y, et al. Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR\/Cas9-mediated genome editing. Oncotarget. 2017;8(22):36331.","journal-title":"Oncotarget"},{"issue":"2","key":"1884_CR10","first-page":"30","volume":"11","author":"SS Tehrani","year":"2021","unstructured":"Tehrani SS, et al. MicroRNA-26a-5p as a potential predictive factor for determining the effectiveness of trastuzumab therapy in HER-2 positive breast cancer patients. Biomedicine. 2021;11(2):30.","journal-title":"Biomedicine"},{"issue":"1","key":"1884_CR11","first-page":"10","volume":"11","author":"A Applebaum","year":"2017","unstructured":"Applebaum A. Is gene therapy a viable option for cancer treatment? Sci J Lander Coll Arts Sci. 2017;11(1):10.","journal-title":"Sci J Lander Coll Arts Sci"},{"issue":"1","key":"1884_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11033-023-09096-8","volume":"51","author":"A Zafar","year":"2024","unstructured":"Zafar A, et al. Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy. Mol Biol Rep. 2024;51(1):219.","journal-title":"Mol Biol Rep"},{"issue":"5","key":"1884_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.20546\/ijcmas.2024.1305.022","volume":"13","author":"M Shokoohi","year":"2024","unstructured":"Shokoohi M. Investigating the anticancer potential of Eisenia fetida coelomic fluid: a comparative study of extraction methods and effects on breast cancer cell lines. Int J Curr Microbiol App Sci. 2024;13(5):169\u201377.","journal-title":"Int J Curr Microbiol App Sci"},{"issue":"1","key":"1884_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/ijms18010085","volume":"18","author":"A Toss","year":"2017","unstructured":"Toss A, et al. Molecular biomarkers for prediction of targeted therapy response in metastatic breast cancer: trick or treat? Int J Mol Sci. 2017;18(1):85.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1884_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/14737140.2017.1374175","volume":"17","author":"R Paterson","year":"2017","unstructured":"Paterson R, Phillips K-A. Genetic testing in women with breast cancer: implications for treatment. Expert Rev Anticancer Ther. 2017;17(11):991\u20131002.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6127","key":"1884_CR16","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, et al. Cancer genome landscapes. Science. 2013;339(6127):1546\u201358.","journal-title":"Science"},{"issue":"6","key":"1884_CR17","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1172\/JCI89914","volume":"127","author":"KM Havas","year":"2017","unstructured":"Havas KM, et al. Metabolic shifts in residual breast cancer drive tumor recurrence. J Clin Investig. 2017;127(6):2091\u2013105.","journal-title":"J Clin Investig"},{"issue":"5","key":"1884_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/14712598.2017.1305351","volume":"17","author":"G Bottai","year":"2017","unstructured":"Bottai G, et al. Progress in nonviral gene therapy for breast cancer and what comes next? Expert Opin Biol Ther. 2017;17(5):595\u2013611.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"1884_CR19","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/cncr.29882","volume":"122","author":"V Verma","year":"2016","unstructured":"Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. Cancer. 2016;122(10):1483\u2013501.","journal-title":"Cancer"},{"issue":"2","key":"1884_CR20","first-page":"142","volume":"2","author":"M Shokoohi","year":"2024","unstructured":"Shokoohi M, Attar T. Biomanufacturing for a sustainable future: unleashing the potential of biotechnology in pharmaceutical raw material production. Int J N Find Health Educ Sci (IJHES). 2024;2(2):142\u201353.","journal-title":"Int J N Find Health Educ Sci (IJHES)"},{"issue":"1","key":"1884_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/cbf.3676","volume":"40","author":"NT Dastjerd","year":"2022","unstructured":"Dastjerd NT, et al. Gene therapy: a promising approach for breast cancer treatment. Cell Biochem Funct. 2022;40(1):28\u201348.","journal-title":"Cell Biochem Funct"},{"issue":"6","key":"1884_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.33263\/BRIAC136.567","volume":"13","author":"K Hadipour","year":"2023","unstructured":"Hadipour K, et al. A comparative review on genome editing approaches. Biointerface Res Appl Chem. 2023;13(6):567.","journal-title":"Biointerface Res Appl Chem"},{"key":"1884_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40484-014-0030-x","volume":"2","author":"X Wu","year":"2014","unstructured":"Wu X, Kriz AJ, Sharp PA. Target specificity of the CRISPR-Cas9 system. Quant Biol. 2014;2:59\u201370.","journal-title":"Quant Biol"},{"issue":"11","key":"1884_CR24","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281\u2013308.","journal-title":"Nat Protoc"},{"issue":"3","key":"1884_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrg2749","volume":"11","author":"LA Marraffini","year":"2010","unstructured":"Marraffini LA, Sontheimer EJ. CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. Nat Rev Genet. 2010;11(3):181\u201390.","journal-title":"Nat Rev Genet"},{"issue":"17","key":"1884_CR26","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1111\/febs.13766","volume":"283","author":"FJ Mojica","year":"2016","unstructured":"Mojica FJ, Rodriguez-Valera F. The discovery of CRISPR in archaea and bacteria. FEBS J. 2016;283(17):3162\u20139.","journal-title":"FEBS J"},{"key":"1884_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-015-0784-0","volume":"16","author":"N Wong","year":"2015","unstructured":"Wong N, Liu W, Wang X. WU-CRISPR: characteristics of functional guide RNAs for the CRISPR\/Cas9 system. Genome Biol. 2015;16:1\u20138.","journal-title":"Genome Biol"},{"issue":"8","key":"1884_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105779","volume":"9","author":"K Li","year":"2014","unstructured":"Li K, et al. Optimization of genome engineering approaches with the CRISPR\/Cas9 system. PLoS ONE. 2014;9(8): e105779.","journal-title":"PLoS ONE"},{"issue":"1","key":"1884_CR29","first-page":"90","volume":"57","author":"R Mohammadhassan","year":"2022","unstructured":"Mohammadhassan R, Ebli PE, Behrouz MA. CRISPR technology for diagnosis: a brief review\u2014CRISPR for diagnosis. Everymans Sci. 2022;57(1):90.","journal-title":"Everymans Sci"},{"issue":"5","key":"1884_CR30","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1667\/RR3123.1","volume":"179","author":"R Taleei","year":"2013","unstructured":"Taleei R, Nikjoo H. The non-homologous end-joining (NHEJ) pathway for the repair of DNA double-strand breaks: I. A mathematical model. Radiat Res. 2013;179(5):530\u20139.","journal-title":"Radiat Res"},{"issue":"1","key":"1884_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","volume":"79","author":"MR Lieber","year":"2010","unstructured":"Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem. 2010;79(1):181\u2013211.","journal-title":"Annu Rev Biochem"},{"key":"1884_CR32","volume-title":"CRISPR technology-recent advances","author":"R Mohammadhassan","year":"2022","unstructured":"Mohammadhassan R, et al. The prominent characteristics of the effective sgRNA for a precise CRISPR genome editing. In: Chen YC, editor., et al., CRISPR technology-recent advances. London: IntechOpen; 2022."},{"issue":"1","key":"1884_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/biomedicines10010107","volume":"10","author":"N Gurumoorthy","year":"2022","unstructured":"Gurumoorthy N, et al. Non-integrating lentiviral vectors in clinical applications: a glance through. Biomedicines. 2022;10(1):107.","journal-title":"Biomedicines"},{"issue":"2","key":"1884_CR34","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.3390\/curroncol30020152","volume":"30","author":"AA Rabaan","year":"2023","unstructured":"Rabaan AA, et al. Application of CRISPR\/Cas9 technology in cancer treatment: a future direction. Curr Oncol. 2023;30(2):1954\u201376.","journal-title":"Curr Oncol"},{"issue":"9","key":"1884_CR35","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.2951","volume":"32","author":"D Heckl","year":"2014","unstructured":"Heckl D, et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol. 2014;32(9):941\u20136.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1884_CR36","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1038\/s41467-019-10421-8","volume":"10","author":"J Xie","year":"2019","unstructured":"Xie J, et al. Efficient base editing for multiple genes and loci in pigs using base editors. Nat Commun. 2019;10(1):2852.","journal-title":"Nat Commun"},{"issue":"6","key":"1884_CR37","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.cell.2020.04.048","volume":"181","author":"S Bowling","year":"2020","unstructured":"Bowling S, et al. An engineered CRISPR-Cas9 mouse line for simultaneous readout of lineage histories and gene expression profiles in single cells. Cell. 2020;181(6):1410-1422. e27.","journal-title":"Cell"},{"issue":"1","key":"1884_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s11658-022-00348-2","volume":"27","author":"M Vaghari-Tabari","year":"2022","unstructured":"Vaghari-Tabari M, et al. CRISPR\/Cas9 gene editing: a new approach for overcoming drug resistance in cancer. Cell Mol Biol Lett. 2022;27(1):49.","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"1884_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12943-023-01738-6","volume":"22","author":"Z Liu","year":"2023","unstructured":"Liu Z, et al. Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy. Mol Cancer. 2023;22(1):35.","journal-title":"Mol Cancer"},{"key":"1884_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113986","volume":"177","author":"AM Malfitano","year":"2020","unstructured":"Malfitano AM, et al. Virotherapy: from single agents to combinatorial treatments. Biochem Pharmacol. 2020;177: 113986.","journal-title":"Biochem Pharmacol"},{"key":"1884_CR41","volume-title":"Encyclopedia of cancer","author":"M Schwab","year":"2008","unstructured":"Schwab M. Encyclopedia of cancer. Heidelberg: Springer Science and Business Media; 2008."},{"issue":"7","key":"1884_CR42","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658\u201370.","journal-title":"Nat Biotechnol"},{"key":"1884_CR43","first-page":"2022","volume":"19","author":"JC Bell","year":"2020","unstructured":"Bell JC. How oncolytic virus therapy is changing cancer treatment. Cancer Res Inst. 2020;19:2022.","journal-title":"Cancer Res Inst"},{"key":"1884_CR44","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3389\/fonc.2020.01786","volume":"10","author":"G-D Cao","year":"2020","unstructured":"Cao G-D, et al. RETRACTED: the oncolytic virus in cancer diagnosis and treatment. Front Oncol. 2020;10:1786.","journal-title":"Front Oncol"},{"issue":"4","key":"1884_CR45","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2217\/fvl-2016-0129","volume":"12","author":"J Maroun","year":"2017","unstructured":"Maroun J, et al. Designing and building oncolytic viruses. Futur Virol. 2017;12(4):193\u2013213.","journal-title":"Futur Virol"},{"issue":"2","key":"1884_CR46","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1074377","volume":"5","author":"O Hemminki","year":"2016","unstructured":"Hemminki O, Hemminki A. A century of oncolysis evolves into oncolytic immunotherapy. Oncoimmunology. 2016;5(2): e1074377.","journal-title":"Oncoimmunology"},{"issue":"3","key":"1884_CR47","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejmhg.2017.10.006","volume":"19","author":"MG Gopisankar","year":"2018","unstructured":"Gopisankar MG, Surendiran A. Oncolytic virotherapy\u2014a novel strategy for cancer therapy. Egypt J Med Hum Genet. 2018;19(3):165\u20139.","journal-title":"Egypt J Med Hum Genet"},{"issue":"21","key":"1884_CR48","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.3390\/cancers13215452","volume":"13","author":"MM Rahman","year":"2021","unstructured":"Rahman MM, McFadden G. Oncolytic viruses: newest frontier for cancer immunotherapy. Cancers. 2021;13(21):5452.","journal-title":"Cancers"},{"key":"1884_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104041","volume":"348","author":"Y Li","year":"2020","unstructured":"Li Y, et al. Oncolytic adenovirus targeting TGF-\u03b2 enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer. Cell Immunol. 2020;348: 104041.","journal-title":"Cell Immunol"},{"issue":"7","key":"1884_CR50","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/v10070352","volume":"10","author":"L Menotti","year":"2018","unstructured":"Menotti L, et al. HSV as a platform for the generation of retargeted, armed, and reporter-expressing oncolytic viruses. Viruses. 2018;10(7):352.","journal-title":"Viruses"},{"key":"1884_CR51","doi-asserted-by":"publisher","first-page":"184954352098319","DOI":"10.1177\/1849543520983196","volume":"7","author":"J Padayachee","year":"2020","unstructured":"Padayachee J, Singh M. Therapeutic applications of CRISPR\/Cas9 in breast cancer and delivery potential of gold nanomaterials. Nanobiomedicine. 2020;7:1849543520983196.","journal-title":"Nanobiomedicine"},{"issue":"2","key":"1884_CR52","doi-asserted-by":"publisher","first-page":"116","DOI":"10.14218\/GE.2023.00154","volume":"23","author":"N Rangel","year":"2024","unstructured":"Rangel N, et al. Exploring the advantages and limitations of CRISPR-cas in breast cancer. Gene Expr. 2024;23(2):116\u201326.","journal-title":"Gene Expr"},{"issue":"30","key":"1884_CR53","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1038\/onc.2013.368","volume":"33","author":"R Nair","year":"2014","unstructured":"Nair R, et al. c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene. 2014;33(30):3992\u20134002.","journal-title":"Oncogene"},{"issue":"4905","key":"1884_CR54","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"W Godolphin","year":"1989","unstructured":"Godolphin W, et al. Studies of the HER-2\/neu protooncogene in human breast and ovarian cancer. Science. 1989;244(4905):707\u201312.","journal-title":"Science"},{"key":"1884_CR55","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.canlet.2016.10.033","volume":"385","author":"H Wang","year":"2017","unstructured":"Wang H, Sun W. CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation. Cancer Lett. 2017;385:137\u201343.","journal-title":"Cancer Lett"},{"issue":"13_supplement","key":"1884_CR56","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1158\/1538-7445.AM2017-2431","volume":"77","author":"X Wang","year":"2017","unstructured":"Wang X, et al. Single cell gene expression profiling in breast cancer cells with the Her2\/neu gene knockout by CRISPR-Cas9. Cancer Res. 2017;77(13_supplement):2431\u20132431.","journal-title":"Cancer Res"},{"issue":"2","key":"1884_CR57","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.celrep.2018.03.056","volume":"23","author":"J Schuijers","year":"2018","unstructured":"Schuijers J, et al. Transcriptional dysregulation of MYC reveals common enhancer-docking mechanism. Cell Rep. 2018;23(2):349\u201360.","journal-title":"Cell Rep"},{"issue":"11","key":"1884_CR58","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1002\/1878-0261.13493","volume":"17","author":"M Kazimierska","year":"2023","unstructured":"Kazimierska M, et al. CRISPR\/Cas9 screen for genome-wide interrogation of essential MYC-bound E-boxes in cancer cells. Mol Oncol. 2023;17(11):2295\u2013313.","journal-title":"Mol Oncol"},{"issue":"24","key":"1884_CR59","doi-asserted-by":"publisher","first-page":"6090","DOI":"10.1158\/0008-5472.CAN-21-2555","volume":"81","author":"X Zhao","year":"2021","unstructured":"Zhao X, et al. Combinatorial CRISPR\/Cas9 screening reveals epistatic networks of interacting tumor suppressor genes and therapeutic targets in human breast cancer. Can Res. 2021;81(24):6090\u2013105.","journal-title":"Can Res"},{"issue":"15","key":"1884_CR60","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1016\/j.molcel.2021.06.014","volume":"81","author":"JM Einstein","year":"2021","unstructured":"Einstein JM, et al. Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. Mol Cell. 2021;81(15):3048-3064.e9.","journal-title":"Mol Cell"},{"issue":"4","key":"1884_CR61","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.stem.2013.03.006","volume":"12","author":"Q Ding","year":"2013","unstructured":"Ding Q, et al. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell. 2013;12(4):393\u20134.","journal-title":"Cell Stem Cell"},{"issue":"6488","key":"1884_CR62","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1126\/science.aba8853","volume":"368","author":"RT Walton","year":"2020","unstructured":"Walton RT, et al. Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. Science. 2020;368(6488):290\u20136.","journal-title":"Science"},{"issue":"7745","key":"1884_CR63","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/d41586-019-00673-1","volume":"566","author":"D Cyranoski","year":"2019","unstructured":"Cyranoski D. The CRISPR-baby scandal: what\u2019s next for human gene-editing. Nature. 2019;566(7745):440\u20133.","journal-title":"Nature"},{"issue":"7","key":"1884_CR64","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41417-020-00265-6","volume":"28","author":"S Chaurasiya","year":"2021","unstructured":"Chaurasiya S, Fong Y. Viroimmunotherapy for breast cancer: promises, problems and future directions. Cancer Gene Ther. 2021;28(7):757\u201368.","journal-title":"Cancer Gene Ther"},{"key":"1884_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.803050","volume":"11","author":"ME Carter","year":"2021","unstructured":"Carter ME, et al. Clinical trials of oncolytic viruses in breast cancer. Front Oncol. 2021;11: 803050.","journal-title":"Front Oncol"},{"issue":"2","key":"1884_CR66","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/mt.2009.266","volume":"18","author":"M Yamamoto","year":"2010","unstructured":"Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol Ther. 2010;18(2):243\u201350.","journal-title":"Mol Ther"},{"issue":"9","key":"1884_CR67","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1158\/1535-7163.MCT-15-0819","volume":"15","author":"I Liikanen","year":"2016","unstructured":"Liikanen I, et al. Oncolytic adenovirus expressing monoclonal antibody trastuzumab for treatment of HER2-positive cancer. Mol Cancer Ther. 2016;15(9):2259\u201369.","journal-title":"Mol Cancer Ther"},{"issue":"15\u201316","key":"1884_CR68","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1089\/hum.2020.078","volume":"31","author":"W Xu","year":"2020","unstructured":"Xu W, et al. LyP-1-modified oncolytic adenoviruses targeting transforming growth factor \u03b2 inhibit tumor growth and metastases and augment immune checkpoint inhibitor therapy in breast cancer mouse models. Hum Gene Ther. 2020;31(15\u201316):863\u201380.","journal-title":"Hum Gene Ther"},{"key":"1884_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-9966-31-51","volume":"31","author":"W Zhu","year":"2012","unstructured":"Zhu W, et al. Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo. J Exp Clin Cancer Res. 2012;31:1\u201310.","journal-title":"J Exp Clin Cancer Res"},{"key":"1884_CR70","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-1-4939-2727-2_12","volume-title":"Gene therapy of solid cancers: methods and protocols","author":"C Thirukkumaran","year":"2015","unstructured":"Thirukkumaran C, Morris DG. Oncolytic viral therapy using reovirus. In: Walther W, Stein U, editors. Gene therapy of solid cancers: methods and protocols. New York: Springer; 2015. p. 187\u2013223."},{"key":"1884_CR71","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01411-19","author":"RM Rodr\u00edguez Stewart","year":"2019","unstructured":"Rodr\u00edguez Stewart RM, et al. Enhanced killing of triple-negative breast cancer cells by reassortant reovirus and topoisomerase inhibitors. J Virol. 2019. https:\/\/doi.org\/10.1128\/jvi.01411-19.","journal-title":"J Virol"},{"issue":"6","key":"1884_CR72","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/cancers10060205","volume":"10","author":"AA Mostafa","year":"2018","unstructured":"Mostafa AA, et al. Oncolytic reovirus and immune checkpoint inhibition as a novel immunotherapeutic strategy for breast cancer. Cancers. 2018;10(6):205.","journal-title":"Cancers"},{"issue":"6","key":"1884_CR73","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/mt.2009.58","volume":"17","author":"P Marcato","year":"2009","unstructured":"Marcato P, et al. Oncolytic reovirus effectively targets breast cancer stem cells. Mol Ther. 2009;17(6):972\u20139.","journal-title":"Mol Ther"},{"issue":"9","key":"1884_CR74","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642\u201362.","journal-title":"Nat Rev Drug Discov"},{"key":"1884_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-014-0223-y","volume":"12","author":"A Marchini","year":"2015","unstructured":"Marchini A, et al. Oncolytic parvoviruses: from basic virology to clinical applications. Virol J. 2015;12:1\u201316.","journal-title":"Virol J"},{"issue":"9","key":"1884_CR76","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/term.2909","volume":"13","author":"JA Tickle","year":"2019","unstructured":"Tickle JA, Chari DM. Less is more: Investigating the influence of cellular nanoparticle load on transfection outcomes in neural cells. J Tissue Eng Regen Med. 2019;13(9):1732\u20137.","journal-title":"J Tissue Eng Regen Med"},{"issue":"10","key":"1884_CR77","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3390\/genes12101517","volume":"12","author":"NR Soares","year":"2021","unstructured":"Soares NR, et al. Meiosis in polyploids and implications for genetic mapping: a review. Genes. 2021;12(10):1517.","journal-title":"Genes"},{"issue":"37","key":"1884_CR78","doi-asserted-by":"publisher","first-page":"11655","DOI":"10.1021\/jacs.8b05042","volume":"140","author":"S Hoshika","year":"2018","unstructured":"Hoshika S, et al. \u201cSkinny\u201d and \u201cFat\u201d DNA: two new double helices. J Am Chem Soc. 2018;140(37):11655\u201360.","journal-title":"J Am Chem Soc"},{"issue":"2","key":"1884_CR79","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/genes8020065","volume":"8","author":"CL Hardee","year":"2017","unstructured":"Hardee CL, et al. Advances in non-viral DNA vectors for gene therapy. Genes. 2017;8(2):65.","journal-title":"Genes"},{"issue":"7","key":"1884_CR80","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41434-020-0163-7","volume":"27","author":"D Wang","year":"2020","unstructured":"Wang D, Wang K, Cai Y. An overview of development in gene therapeutics in China. Gene Ther. 2020;27(7):338\u201348.","journal-title":"Gene Ther"},{"issue":"1","key":"1884_CR81","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1146\/annurev-virology-092818-015530","volume":"6","author":"AM Keeler","year":"2019","unstructured":"Keeler AM, Flotte TR. Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): where are we, and how did we get here? Annu Rev Virol. 2019;6(1):601\u201321.","journal-title":"Annu Rev Virol"},{"issue":"7","key":"1884_CR82","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.drudis.2021.03.021","volume":"26","author":"NA Alhakamy","year":"2021","unstructured":"Alhakamy NA, Curiel DT, Berkland CJ. The era of gene therapy: from preclinical development to clinical application. Drug Discov Today. 2021;26(7):1602\u201319.","journal-title":"Drug Discov Today"},{"issue":"6","key":"1884_CR83","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3892\/ijo_00000619","volume":"36","author":"EM Gordon","year":"2010","unstructured":"Gordon EM, Hall FL. Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent. Int J Oncol. 2010;36(6):1341\u201353.","journal-title":"Int J Oncol"},{"issue":"5","key":"1884_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3015","volume":"20","author":"SL Ginn","year":"2018","unstructured":"Ginn SL, et al. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. 2018;20(5): e3015.","journal-title":"J Gene Med"},{"issue":"1","key":"1884_CR85","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian SA, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107\u201317.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1884_CR86","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1172\/JCI60534","volume":"121","author":"K Polyak","year":"2011","unstructured":"Polyak K. Heterogeneity in breast cancer. J Clin Investig. 2011;121(10):3786\u20138.","journal-title":"J Clin Investig"},{"key":"1884_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.783494","volume":"9","author":"S Mehmood","year":"2022","unstructured":"Mehmood S, et al. Breast cancer resistance likelihood and personalized treatment through integrated multiomics. Front Mol Biosci. 2022;9: 783494.","journal-title":"Front Mol Biosci"},{"key":"1884_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155509","volume":"261","author":"MDM Abas","year":"2024","unstructured":"Abas MDM, et al. Advancements of gene therapy in cancer treatment: a comprehensive review. Pathol Res Pract. 2024;261: 155509.","journal-title":"Pathol Res Pract"},{"issue":"3","key":"1884_CR89","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.3390\/molecules28031498","volume":"28","author":"GYW Tseu","year":"2023","unstructured":"Tseu GYW, Kamaruzaman KA. A review of different types of liposomes and their advancements as a form of gene therapy treatment for breast cancer. Molecules. 2023;28(3):1498.","journal-title":"Molecules"},{"issue":"8","key":"1884_CR90","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3390\/jpm11080808","volume":"11","author":"A Burguin","year":"2021","unstructured":"Burguin A, Diorio C, Durocher F. Breast cancer treatments: updates and new challenges. J Personal Med. 2021;11(8):808.","journal-title":"J Personal Med"},{"issue":"5","key":"1884_CR91","doi-asserted-by":"publisher","first-page":"47","DOI":"10.53388\/TMR20220320003","volume":"7","author":"H Marawne","year":"2022","unstructured":"Marawne H, et al. Valerian (Valeriana officinalis) extract inhibits TNF-\u03b1 and iNOS gene expression in mouse LPS-activated microglial cells. Tradit Med Res. 2022;7(5):47.","journal-title":"Tradit Med Res"},{"issue":"7","key":"1884_CR92","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1167\/iovs.64.7.39","volume":"64","author":"S Drag","year":"2023","unstructured":"Drag S, Dotiwala F, Upadhyay AK. Gene therapy for retinal degenerative diseases: progress, challenges, and future directions. Invest Ophthalmol Vis Sci. 2023;64(7):39\u201339.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"1884_CR93","first-page":"283","volume":"32","author":"OD Abaan","year":"2002","unstructured":"Abaan OD, Criss WE. Gene therapy in human breast cancer. Turk J Med Sci. 2002;32(4):283\u201391.","journal-title":"Turk J Med Sci"},{"key":"1884_CR94","first-page":"237","volume-title":"Stem cells and good manufacturing practices methods, protocols, and regulations","author":"B Arjmand","year":"2021","unstructured":"Arjmand B, et al. GMP-compliant adenoviral vectors for gene therapy. In: Turksen K, editor., et al., Stem cells and good manufacturing practices methods, protocols, and regulations. New York: Springer; 2021. p. 237\u201350."},{"issue":"31","key":"1884_CR95","doi-asserted-by":"publisher","first-page":"30675","DOI":"10.18632\/oncotarget.5169","volume":"6","author":"S Chira","year":"2015","unstructured":"Chira S, et al. Progresses towards safe and efficient gene therapy vectors. Oncotarget. 2015;6(31):30675.","journal-title":"Oncotarget"},{"issue":"6","key":"1884_CR96","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1021\/acsmaterialsau.3c00035","volume":"3","author":"J Lin","year":"2023","unstructured":"Lin J, et al. Combinational gene therapy toward cancer with nanoplatform: strategies and principles. ACS Mater Au. 2023;3(6):584\u201399.","journal-title":"ACS Mater Au"},{"issue":"2","key":"1884_CR97","first-page":"399","volume":"13","author":"M Kr\u00f3l","year":"2010","unstructured":"Kr\u00f3l M, et al. Why chemotherapy can fail. Pol J Vet Sci. 2010;13(2):399\u2013406.","journal-title":"Pol J Vet Sci"},{"issue":"5","key":"1884_CR98","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1039\/c0ib00142b","volume":"3","author":"B Fallica","year":"2011","unstructured":"Fallica B, Makin G, Zaman MH. Bioengineering approaches to study multidrug resistance in tumor cells. Integr Biol. 2011;3(5):529\u201339.","journal-title":"Integr Biol"},{"issue":"3","key":"1884_CR99","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S1525-0016(03)00203-X","volume":"8","author":"T Lin","year":"2003","unstructured":"Lin T, et al. Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. Mol Ther. 2003;8(3):441\u20138.","journal-title":"Mol Ther"},{"issue":"12","key":"1884_CR100","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1093\/annonc\/mds586","volume":"23","author":"S Guiu","year":"2012","unstructured":"Guiu S, et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 working group statement. Ann Oncol. 2012;23(12):2997\u20133006.","journal-title":"Ann Oncol"},{"key":"1884_CR101","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S48887","author":"NS Abul-Husn","year":"2014","unstructured":"Abul-Husn NS, et al. Implementation and utilization of genetic testing in personalized medicine. Pharmacogen Personal Med. 2014. https:\/\/doi.org\/10.2147\/PGPM.S48887.","journal-title":"Pharmacogen Personal Med"},{"key":"1884_CR102","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1038\/modpathol.2010.37","volume":"23","author":"L Da Silva","year":"2010","unstructured":"Da Silva L, Lakhani SR. Pathology of hereditary breast cancer. Mod Pathol. 2010;23:S46\u201351.","journal-title":"Mod Pathol"},{"issue":"20","key":"1884_CR103","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJM199705153362002","volume":"336","author":"FJ Couch","year":"1997","unstructured":"Couch FJ, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997;336(20):1409\u201315.","journal-title":"N Engl J Med"},{"issue":"5645","key":"1884_CR104","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"M-C King","year":"2003","unstructured":"King M-C, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643\u20136.","journal-title":"Science"},{"issue":"9","key":"1884_CR105","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/nrclinonc.2012.123","volume":"9","author":"KN Maxwell","year":"2012","unstructured":"Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol. 2012;9(9):520\u20138.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01884-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-01884-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01884-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T08:28:17Z","timestamp":1738916897000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-01884-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1884"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-01884-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}